Search alternatives:
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
marked decrease » marked increase (Expand Search)
date reported » data reported (Expand Search), fate reporter (Expand Search), cases reported (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
marked decrease » marked increase (Expand Search)
date reported » data reported (Expand Search), fate reporter (Expand Search), cases reported (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
Self-Report Questionnaires.
Published 2025“…Biomarker analyses suggest possible prolonged inflammatory processes in long COVID patients compared to fully recovered patients. Results of decreased neuroplastic functioning give credence to patients’ reports of post-COVID changes in brain function.…”
-
7
Characteristics of AEs reports.
Published 2025“…</p><p>Methods</p><p>This research implemented a disproportionality analysis to assess the safety of toripalimab by reviewing all adverse event reports from the FAERS database dating back to 2004, wherein toripalimab was recognized as the main suspected medication. …”
-
8
-
9
Image 2_Computed tomography and magnetic resonance imaging features of primary liver perivascular epithelioid cell tumor with renal angiomyolipoma: a case report and literature rev...
Published 2025“…The enhancement slightly decreased in the equilibrium phase and the delayed phase. …”
-
10
Image 1_Computed tomography and magnetic resonance imaging features of primary liver perivascular epithelioid cell tumor with renal angiomyolipoma: a case report and literature rev...
Published 2025“…The enhancement slightly decreased in the equilibrium phase and the delayed phase. …”
-
11
Data Sheet 1_Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure.pdf
Published 2025“…Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. …”
-
12
Data Sheet 1_Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and...
Published 2025“…Introduction<p>To date, only two drugs, pirfenidone and nintedanib, are approved for the treatment of patients with idiopathic pulmonary fibrosis (IPF). …”
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20